| Serial Number | 97923896 |
| Word Mark | ELEVIDYS |
| Filing Date | Saturday, May 6, 2023 |
| Status | 602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE |
| Status Date | Wednesday, May 22, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s) |
| Published for Opposition Date | NOT AVAILABLE |
| Description of Mark | The mark consists of three alternately-shaded semicircles increasing in size to an oval center and three alternately-shaded semicircles decreasing in size on the other side of the oval center and followed by 'Elevidys.' The color gray is intended to show shading or contrast only. |
| Goods and Services | Pharmaceutical preparations for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations based on morpholino oligomer technology platform for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; Pharmaceutical preparations that modulate RNA expression for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; Gene therapy products, namely, gene delivery pharmaceuticals; Pharmaceutical preparations for gene therapy, gene editing, and genome editing; Gene therapies for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Biological preparations for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Viruses, viral vectors and viral constructs for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations, biological preparations and gene therapy products in the nature of pharmaceutical and biological preparations for the treatment of genetic disorders and diseases |
| Indication of Colors claimed | Color is not claimed as a feature of the mark. |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Monday, June 5, 2023 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Sarepta Therapeutics, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Cambridge, MA 02142 |
| Event Date | Event Description |
| Wednesday, May 10, 2023 | NEW APPLICATION ENTERED |
| Monday, June 5, 2023 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Tuesday, June 6, 2023 | NOTICE OF DESIGN SEARCH CODE E-MAILED |
| Wednesday, January 31, 2024 | ASSIGNED TO EXAMINER |
| Tuesday, February 6, 2024 | NON-FINAL ACTION WRITTEN |
| Tuesday, February 6, 2024 | NON-FINAL ACTION E-MAILED |
| Tuesday, February 6, 2024 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Wednesday, May 22, 2024 | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND |
| Wednesday, May 22, 2024 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE |